PLMA_1170x120_10-8-21

Pharmaceutical Care Management Association (PCMA)

PCMA issues statement on rebate rule repeal in budget bill

PCMA issues statement on rebate rule repeal in budget bill

WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and CEO JC Scott issued the following statement on the Ways and Means Committee’s inclusion of full repeal of the rebate rule in the committee’s “Build Back Better Act:” “We applaud chairman Richard Neal, and members of the Ways and Means Committee, for including a permanent repeal

PCMA issues statement on the Biden Administration’s drug pricing plan

PCMA issues statement on the Biden Administration’s drug pricing plan

WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and CEO JC Scott issued the following statement on the Biden administration’s plan for high drug prices: “While we review the recently released Comprehensive Plan for Addressing High Drug Prices report, America’s pharmacy benefit managers, PBMs, applaud the Administration for its focus on reducing prescription drug costs for patients

PCMA urges congress to pass more medical assisted treatment access

PCMA urges congress to pass more medical assisted treatment access

WASHINGTON — As the “National Call-In Day” takes place in support of the bipartisan “Mainstreaming Addiction Treatment Act,” reintroduced in February by U.S. Senators Maggie Hassan (D-NH) and Lisa Murkowski (R-AK) and Representatives Paul D. Tonko (D-NY) and Michael Turner (R-OH), Pharmaceutical Care Management Association (PCMA) president and CEO JC Scott released the following statement:

PCMA announces Virtual PBM Policy Forum 2021

PCMA announces Virtual PBM Policy Forum 2021

WASHINGTON — Today, the Pharmaceutical Care Management Association (PCMA) announced the Virtual PBM Policy Forum 2021, featuring health care, pharmacy benefit managers (PBMs), and pharmaceutical manufacturer industry thought leaders and executives discussing how the public and private sectors are tackling drug costs and improving the affordability and quality of care for patients. “We are pleased

PCMA: Drug manufacturers’ pricing tactics reduce competition, increase Rx drug costs

PCMA: Drug manufacturers’ pricing tactics reduce competition, increase Rx drug costs

WASHINGTON — As the House Committee on Oversight and Reform continues its investigation into drug manufacturers’ pricing strategies, the Pharmaceutical Care Management Association (PCMA) is releasing new data on the impact of blocking competition for top-selling medications. Brand-name drug manufacturers use “patent thickets” to block generic or biosimilar competition from entering the market. For Humira, Enbrel,

PCMA unveils three-part policy platform to reduce prescription drug costs

PCMA unveils three-part policy platform to reduce prescription drug costs

WASHINGTON — The Pharmaceutical Care Management Association (PCMA) is announcing a new three-part policy platform, supported by America’s pharmacy benefit managers, PBMs, aimed at reducing prescription drug costs by updating Medicare Part D, enhancing competition, and building toward a more value-driven health care system for patients. “PCMA’s multi-faceted policy platform provides specific policy actions to

PCMA praises Biden Administration’s nominees for key Department of HHS positions

PCMA praises Biden Administration’s nominees for key Department of HHS positions

WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and CEO JC Scott issued the following statement on the pending confirmations of three officials of the U.S. Department of Health and Human Services (HHS): Chiquita Brooks-LaSure, nominee for Administrator for the Centers for Medicare & Medicaid Services; Andrea Palm, nominee for Deputy Secretary; Melanie Egorin, nominee

Study: Drug manufacturers undermine Rx cost savings tools, increase drug costs

Study: Drug manufacturers undermine Rx cost savings tools, increase drug costs

WASHINGTON — A new white paper, “Solving America’s High Drug Cost Problem: Prevent Drug Company Tactics that Increase Costs and Undermine Clinical Quality,” by the Pharmacy Benefit Management Institute (PBMI), released today by the Pharmaceutical Care Management Association (PCMA), outlines ways that some drug manufacturers undermine formulary and utilization management tools, resulting in higher drug costs

PCMA on National Diabetes Month: PBMs lowering insulin costs, providing support to patients

PCMA on National Diabetes Month: PBMs lowering insulin costs, providing support to patients

WASHINGTON — In recognition of National Diabetes Month, the Pharmaceutical Care Management Association (PCMA) is outlining how pharmacy benefit managers, PBMs, are working to lower insulin costs and creating programs to support people with diabetes and improve health outcomes. “PBMs have been able to moderate insulin costs for most people with insurance,” said PCMA president and CEO

Groups praise high court for hearing Rutledge case

Groups praise high court for hearing Rutledge case

ALEXANDRIA, Va. — Groups ranging from the National Community Pharmacists Association (NCPA) to the Food Industry Association (FMI) have applauded the Supreme Court for hearing Rutledge v. Pharmaceutical Care Management Association (PCMA). This historic case seeks to clarify whether states can regulate pharmacy benefit managers, which manage prescription drug benefits for health insurers, Medicare Part

PBMs continue to keep Medicare part D premiums affordable

PBMs continue to keep Medicare part D premiums affordable

WASHINGTON— Pharmaceutical Care Management Association president and CEO JC Scott issued the following statement on the open enrollment season for the Medicare Part D prescription drug benefit: “As open enrollment begins, we are encouraged to see the continued trend of affordability and low premiums for seniors under Medicare Part D. This trend in affordability is due

PCMA issues statement on Medicare Part D premiums

PCMA issues statement on Medicare Part D premiums

WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and CEO JC Scott issued the following statement on the Administration’s announcement on 2021 Medicare Part D premiums: “PCMA applauds the Administration for its work continuing the success of the Part D program. Today’s announcement shows that the 2021 and 2020 average basic premiums are the second

CMA issues statement on Administration’s executive order on Rx drug pricing

CMA issues statement on Administration’s executive order on Rx drug pricing

WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and CEO JC Scott issued the following statement on the Administration’s Executive Order to resurrect the rebate rule: “The Administration’s decision last year to withdraw a proposed regulation on prescription drug rebates was the right decision. Reviving a rebate reform proposal now does not address the underlying

PCMA applauds Trump Administration on new program to reduce insulin costs for medicare enrollees  

PCMA applauds Trump Administration on new program to reduce insulin costs for medicare enrollees  

WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and chief executive officer JC Scott issued on Tuesday the following statement applauding the Administration’s initiative, announced today, to reduce insulin costs for Medicare enrollees: “We commend the Administration for allowing Part D plan sponsors to offer a new, voluntary Medicare Part D plan, starting in 2021, under which

1 2 3